Key Takeaways
- Ex-US overtakes US, ahead of plan: Ex-US revenue reached 102% of US revenue in Q2 FY27, a milestone originally set for FY28, driven by 31% YoY growth and broad-based momentum across every market.
- US recovery begins, but FY28 aspiration deferred: US revenue grew 9% QoQ to $73 million, and recent B2B wins underpin a stronger H2, yet the ~$375 million FY28 aspiration now shifts "a little beyond FY28" as the company protects margin quality over speed.
- Gross margin compressed by geopolitical cost spikes: Gross margin slipped to 56.0% (from 60.9% QoQ) as purchases made at the height of disruptions flowed through; cost mitigation actions are gaining traction and management is confident of sustaining 58%+ going forward.
- Working capital swells, debt rises: Cash-to-cash cycle rose 13 days to 137 days, and net debt-to-EBITDA ticked up to 1.72x, driven by deliberate inventory build amid longer transit times and revenue growth; improvement expected as the year closes.
- What to watch next quarter: Whether the Sandoz deal closes in Q3 as expected, the pace of cash conversion cycle normalization, and whether H2 US launches (4–6 products) and B2B wins convert into the promised stronger second half.
The Ex-US Inflection
- Milestone achieved early: Ex-US revenue hit 102% of US revenue in Q2 FY27, a goal originally set for FY28; management now expects Ex-US to contribute more than the US to the FY28 revenue ambition, which remains fully intact.
- Broad-based growth: Every Ex-US market showed healthy momentum, with Q2 revenue growing 31% YoY to ₹696.3 crore; growth was driven by new product launches, base business expansion into new geographies and with new partners.
- Supply chain normalization: Q1 shipment delays were a matter of timing; in Q2, robust supply chain execution delivered without spillovers, and demand and order books across key Ex-US markets remain healthy.
- Market-level highlights: UK prescription business delivered strong pricing and volume momentum; Europe partnered business grew on higher customer offtake; Nordics saw strong QoQ growth with branded products now positioned as first-line treatment in parts of Denmark; Africa's Francophone branded business outpaced the underlying market; South Africa added new products and retail pharmacy chain business.
- Profitability quality: Ex-US EBITDA is expected to be slightly higher than the company average; gross margins and EBITDA are good in these markets, and with growing scale and operating leverage, continued margin expansion is expected.
- Aspiration raised: With current trends, Ex-US revenue is now expected to be "upwards of $375 million in FY28," mirroring the original US aspiration.
Badree Komandur: "Ex-US now stands shoulder to shoulder with the US, not instead of it but alongside it, and that makes Strides stronger as a whole."
US Business: Recovery with Margin Discipline
- Sequential recovery underway: US Q2 revenue at ₹685.5 crore ($73 million) grew 9% YoY and 9% QoQ; management had expected a softer first half and is encouraged by the healthy recovery.
- B2B wins underpin H2: The B2B partner business secured meaningful new business wins during the quarter from a partnered product, recent launches and other key molecules; these wins will show up in coming quarters and support a better H2.
- FY28 aspiration deferred: The ~$375 million US revenue aspiration now expected "a little beyond FY28"; timing moved because the company chose to protect margin quality and profitability discipline rather than launch products that would compromise the profitability fabric.
- Profitability-led growth philosophy: Management will protect established profitability thresholds and drive margin-accretive revenues through selective launches and differentiated platforms; will not compromise on profitability or quality of business to chase revenue.
- Portfolio shifting toward differentiation: Over 40 value-accretive products in the active pipeline with filings and approvals planned through FY30; growth anchored in differentiated platforms (nasal sprays, patches, films) and a steadily expanding Controlled Substances portfolio.
- Controlled Substances ramp: CS business grew from 0% to 6% of US revenue over the last couple of years through progressive quota allocation improvements; growth remains constrained by quota allocations, which are expected to improve progressively.
- CS pipeline built for quota efficiency: Over 10 CS products in the pipeline across nasal sprays, patches and films; these niche products need only limited API quota, enabling faster ramp-up even within today's allocations.
- H2 launch cadence: 4 to 6 US products expected to launch in H2 FY27; products already launched will also see revenues in H2; H2 launches will flow into FY28 for full-year benefit.
- Drug shortage normalization: Shortages have largely normalized across most oral products; shortages persist in injectables and patches; the company is building a strategic portfolio for more predictable growth.
Badree Komandur: "We will not compromise on profitability or the quality of our business to chase revenue."
Differentiated Platforms: Nasal Sprays, Patches, Films
- Third nasal spray filed: A third nasal spray (also a controlled substance) was filed in September 2026, as committed on the last call; the first nasal spray has a GDUFA goal date in H2 FY27 and we expect approval in Q4.
- Transdermal patch relaunch: A controlled-substance patch (acquired from Endo ANDAs) is expected to relaunch in Q3; the full-year benefit will flow into FY28.
- First patch product from acquired IP: The first patch product from IP acquired last year is expected to launch later this year; some acquired IP for Ex-US markets is already playing out, while US-specific IP will flow through over the next 18 months or so.
- Differentiated products timeline: Meaningful contribution from differentiated products is expected in FY28–FY29, a slight delay of about 3–4 quarters, and we should be able to get to that milestone by FY29.
- FY28 aspiration not product-dependent: The FY28 aspiration does not hinge on a particular product; it is broad-based, and the new portfolio being built will start playing out from FY29.
Margins: Compressed but Defended
- Gross margin compression: Gross margin moderated to 56.0% in Q2 (vs 57.8% YoY and 60.9% QoQ), reflecting higher input costs linked to the geopolitical situation; material costs rose to 44% of revenues from 42.2% last year.
- Timing of cost impact: Purchases made in Q4 at the height of geopolitical disruptions were consumed in Q2; cost initiatives put in place when disruptions happened are now starting to play out internally.
- Cost mitigation gaining traction: Cost increases are now moderating and cost improvement programs are gaining traction through alternate sourcing, procurement initiatives and continuous cost optimisation.
- Operating leverage visible: Total operating costs improved 40 bps to 38.4% of revenues despite cost increases, demonstrating operating leverage.
- H1 margin quality: H1 gross margins stood at a healthy 58.3%; Ex-US businesses maintained profitability even as they scaled, supporting margin quality.
- Confidence in sustainability: Management is confident of sustaining H1 gross margins (58.3%) going forward; the gross margin range of 58% to 60% will be maintained at the company level, with every market healthy in margins.
- EBITDA margin: EBITDA margin at 17.6% (vs 19.0% YoY and 18.2% QoQ) as the company absorbed higher material, freight and logistics costs.
- Bottom-line acceleration expected: With the overall FY28 growth aspiration intact and operating leverage playing out, management continues to maintain that the bottom line should accelerate ahead of the top line.
Vikesh Kumar: "We did not want to launch products compromising our fabric of profitability discipline. And that is the reason we felt that it is better to protect the quality of margins and focus on profitability, drive the profitability and EPS margin accretion that we have been known for..."
Balance Sheet: Working Capital Swells, Normalization Expected
- Cash-to-cash cycle extended: Rose to 137 days, up 13 days from March 2026; absolute working capital increased ₹307 crore in H1.
- Inventory build breakdown: ~₹174 crore of the increase reflects deliberate inventory build: higher transit and lead times due to the geopolitical situation, plus deliberate finished goods inventory increase at front-end locations; ~₹133 crore came from 15% revenue growth.
- Net debt rises after quarters of reduction: Net debt-to-EBITDA ratio at 1.72x, reflecting a ₹211 crore increase in net debt during H1 driven by working capital; this is the first quarter of debt increase after 4–5 quarters of consistent reduction.
- Normalization expected: The cash conversion cycle is expected to improve in coming quarters, with cash cycle engines "back in the next quarter itself"; inventory levels will moderate as the year completes, though they will form a new normal at some point.
- Net-debt-free aspiration intact: The aspiration to be net-debt-free has not changed; growth on a consolidated basis remains intact despite the US/Ex-US mix change; the company expects to largely remain working capital debt as it gets to FY29.
- Capex moderating: FY27 capex expected around ₹300 crore; FY28 capex can be slightly lower, including maintenance capex and some intangibles.
- ROCE: Trailing 12-month ROCE at 14.4%, remaining in the 14–15% range; as growth continues and recent investments mature, returns are expected to improve.
Sandoz Deal & Other Updates
- Sandoz deal nearing close: The deal with Sandoz is now awaiting antitrust approval in only a few countries; closure is expected in Q3.
- Ex-US scale post-Sandoz: With Sandoz adding in, Ex-US will reach a very meaningful size in the next 1–2 years and should mirror the US market aspiration.
- New out-licensing deals: Multiple new out-licensing deals were signed in the first half across Europe, strengthening momentum.
- Product launches: Three products launched in Q2, taking the commercialised portfolio from 72 to 75 products.
- Board appointment: Mr. Biren Gabhawala appointed as Independent Director, bringing over three decades of experience in financial reporting, audit, taxation and corporate governance; Independent Directors now make up 6 of 10 Board members.
- LatAm entry: Now in the regulatory phase; will take a couple of years to build and will not contribute meaningfully to growth until about FY29–FY30.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Overall FY28 revenue ambition | Fully intact; regional mix shifts toward Ex-US contributing more than US | FY28 |
| US revenue aspiration (~$375M) | Ambition unchanged, timing moved "a little beyond FY28" | Beyond FY28 |
| Ex-US revenue aspiration | "Upwards of $375 million" | FY28 |
| H2 stronger than H1 | Reiterated; recent B2B wins and 4–6 US launches to underpin better H2 | H2 FY27 |
| Sandoz deal closure | Awaiting antitrust approval in few countries | Q3 FY27 |
| First nasal spray approval | GDUFA goal date in H2 FY27 | Q4 FY27 |
| Transdermal patch relaunch | Controlled-substance patch from Endo ANDAs | Q3 FY27 |
| First acquired-IP patch launch | Acquired IP last year | Later this year |
| Gross margin range | 58% sustained at company level | Ongoing |
| Cash conversion cycle improvement | Cash cycle engines "back in the next quarter itself" | Coming quarters |
| Net debt-to-EBITDA | Expected to stabilise and improve as inventory normalises and H2 launches contribute | By end of year |
| FY27 capex | ~₹300 crore | FY27 |
| FY28 capex | Slightly lower than FY27; includes maintenance capex and intangibles | FY28 |
| Differentiated products meaningful contribution | Slight delay of 3–4 quarters; aiming for FY29 | By FY29 |
| Bottom-line acceleration | Bottom line to accelerate ahead of top line | Ongoing |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue | ₹1,429.7 crore, highest ever, +17% YoY and +13% QoQ |
| Ex-US revenue share | ~49% of total revenue, up from 43% in Q2 last year |
| Gross margin | 56.0%, vs 57.8% in Q2 last year and 60.9% in Q1; higher input costs |
| H1 gross margin | 58.3%, expected to be sustainable |
| EBITDA | ₹250.9 crore, +8% YoY, first time crossing ₹250 crore in a single quarter |
| EBITDA margin | 17.6%, vs 19.0% in Q2 last year and 18.2% in Q1 |
| Operational PAT | ₹135.8 crore, +12% YoY |
| Operational EPS | ₹14.7, vs ₹13.2 in Q2 last year |
| Reported PAT | ₹134 crore; reported EPS ₹14.2 per share |
| US revenue | ₹685.5 crore ($73 million), +9% YoY and +9% QoQ |
| Ex-US revenue | ₹696.3 crore, +31% YoY; crossed US revenue for the first time |
| Ex-US as % of US | 102%, vs 76% in FY25 and 90% in FY26 |
| Material costs | 44% of revenue, vs 42.2% in Q2 last year |
| Freight costs | 5.5% of revenue, up ₹21 crore YoY |
| Total operating costs | 38.4% of revenue, improved 40 bps |
| Depreciation and amortisation | ₹57 crore |
| Net finance cost | ₹43 crore; expected H2 range ₹40–45 crore |
| EBITDA to operational PAT conversion | 54% |
| Cash-to-cash cycle | 137 days, up 13 days from March 2026 |
| Net debt-to-EBITDA ratio | 1.72x, reflecting ₹211 crore increase in net debt during H1 driven by working capital |
| Trailing 12-month ROCE | 14.4%, in the 14–15% range |
| ANDAs filed / approved | 230 filed, 212 approved as of October 2026, covering 154 products |
| Commercialised products | 75, up from 72 at end of Q1; 3 products launched in Q2 |
| Top-3 market position products | 38 products, contributing ~70% of US revenue |
| Controlled Substances revenue share | ~6% of US revenue, from 5 commercialised products |
| Controlled Substances pipeline addressable market | ~$4.5 billion, ~6x the current ~$750 million market |
| Value-accretive pipeline products | >40, with filings and approvals planned through FY30 |
| Non-CS differentiated pipeline products | >25 |
| H1 FY27 revenue | ₹2,695 crore, +15.1% |
| H1 FY27 EBITDA | ₹481 crore, +6.9%; margin 17.8% |
| H1 FY27 operational PAT | ₹259 crore, +9.8%; operational EPS ₹28.1 per share |
| H1 FY27 reported PAT | ₹300 crore, +26.4%, includes gain on Pivot Path divestment |
| H1 FY27 capex and intangibles deployed | ₹208 crore |
| FY27 capex expected | ~₹300 crore |
| Expected H2 US launches | 4 to 6 products |
| Ex-US FY28 revenue aspiration | Upwards of $375 million |
| US FY28 revenue aspiration | ~$375 million, now expected a little beyond FY28 |